Sacubitril-Valsartan in Patients Requiring Hemodialysis
JAMA Network Open · 2024
DOI: 10.1001/jamanetworkopen.2024.29237 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Dustin Le und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland. Hauptthemen laut MEDLINE: Biphenyl Compounds, Valsartan, Drug Combinations, Aminobutyrates. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Importance Randomized clinical trials have shown that sacubitril-valsartan reduces the risks of mortality and hospitalization in patients with heart failure with reduced ejection fraction (HFrEF), but patients with kidney failure requiring dialysis were excluded.
Objective
To investigate the comparative effectiveness of sacubitril-valsartan vs angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs or ARBs) in patients with HFrEF requiring hemodialysis. Design, Setting, and Participants This retrospective, 1:1 propensity score–matched comparative effectiveness study included patients who were 18 years or older with HFrEF, enrolled in Medicare Parts A, B, and D, and survived at least 90 days receiving in-center hemodialysis from July 8, 2015, to December 31, 2020. Patients were excluded for less than 180 days of continuous Medicare Parts A, B, and D primary payer coverage or prior dispensing of sacubitril-valsartan. Data analysis was conducted from September 23, 2023, to June 25, 2024. Exposures New use of sacubitril-valsartan vs new or continued use of ACEIs or ARBs. Main Outcomes and Measures The associations between initiation of sacubitril-valsartan therapy and all-cause mortality, cardiovascular mortality, all-cause hospitalization, and HF hospitalization were assessed using Cox proportional hazards regression models in a propensity score–matched sample.
Results
Participants included 1:1 matched pairs of 1434 sacubitril-valsartan users and 1434 ACEI or ARB users (mean [SD] age, 64 [13] years). Of the 2868 matched participants, 996 (65%) were male; 987 (34%) were Black or African American and 1677 (58%) were White; and median dialysis vintage was 3.8 (IQR, 1.8-6.3) years. The median follow-up was 0.9 (IQR, 0.4-1.7) years. Sacubitril-valsartan (vs ACEI or ARB) therapy was associated with a reduction in all-cause mortality (hazard ratio [HR], 0.82 [95% CI, 0.73-0.92]) and all-cause hospitalization (HR, 0.86 [95% CI, 0.79-0.93]) but not cardiovascular mortality (HR, 1.01 [95% CI, 0.86-1.19]) or HF hospitalization (HR, 0.91 [95% CI, 0.82-1.02]). There was a decrease in hyperkalemia (HR, 0.71 [95% CI, 0.62-0.81]) and no difference in hypotension (HR, 0.99 [95% CI, 0.83-1.19]). Only 195 participants (14%) ever received the maximum combination dose of sacubitril (97 mg twice daily) and valsartan (103 mg twice daily). Conclusions and Relevance In this comparative effectiveness study of patients with HFrEF requiring hemodialysis, sacubitril-valsartan therapy was associated with beneficial effects in all-cause mortality and all-cause hospitalization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
- Division of Precision Medicine, Department of Medicine, New York University, New York, New York.
- Optimal Aging Institute, Department of Medicine, New York University, New York, New York.
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Le, D., Grams, M. E., Coresh, J., & Shin, J. I. (2024). Sacubitril-Valsartan in Patients Requiring Hemodialysis. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.29237
Vancouver
Le D, Grams ME, Coresh J, Shin JI. Sacubitril-Valsartan in Patients Requiring Hemodialysis. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.29237
BibTeX
@article{Le2024,
author = {Le, Dustin and Grams, Morgan E and Coresh, Josef and Shin, Jung-Im},
title = {Sacubitril-Valsartan in Patients Requiring Hemodialysis},
journal = {JAMA Network Open},
year = {2024},
doi = {10.1001/jamanetworkopen.2024.29237}
}
EUVIMED